We're pleased to announce that the first trial site for Regneron's OPTIMA clinical trial is open and enrolling patients ages 18 and up. The trial site is the Royal National Orthopaedic Hospital in the United Kingdom.

OPTIMA is the phase 3 trial of Regeneron's potential drug treatment for FOP - garetosmab.

You can learn more and read all of the inclusion and exclusion criteria at ifopa.org/optima